Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Oral Thin Film (S)-Ketamine in Healthy Participants
NCT04300621Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of esketamine in treatment-resistant depression (TRD) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Plasma Concentration up to 24 hours, Area Under the Plasma Concentration-time Curve from Time 0 To Time Of the Last Quantifiable Concentrations up to 24 hours and 1 more. Started Jun 2020; status: completed.
02
Drugs
esketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT04300621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04300621.